이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Inflammation and Medical Provider Attitudes, Cognition, and Treatment Decisions Study (IMPACT)

2026년 9월 25일 업데이트: University of Arkansas, Fayetteville

The Impacts of Adverse Provider Conditions on Medical Decision-Making and Patient Care

This is a randomized, double-blind clinical trial involving emergency medicine and internal medicine healthcare providers as participants. The intervention involves the administration of the seasonal influenza vaccine or a saline placebo; this protocol is used in psychoneuro-immunology to simulate a state of mild illness. The primary aim is to examine whether acute inflammation induced by receiving the vaccine affects decision-making on standardized psychological reaction time tasks and questionnaires. Participants attend two laboratory sessions on consecutive days, receive either a seasonal influenza vaccine or a saline placebo at the first session, provide blood samples to measure inflammatory cytokines, and complete a series of standardized assessments of medical decision-making and social attitudes. Participants who received the placebo during the first session will receive the vaccine during the second session.

Overall, the study is designed to examine how adverse provider conditions particularly acute inflammation, burnout, and concerns about one's own health affect provider judgments and healthcare-related decision-making. The primary hypothesis is that providers experiencing greater adverse conditions at the time of research participation would have altered decision-making compared to those experiencing fewer adverse conditions.

연구 개요

상세 설명

Participants will provide informed consent during a call (Zoom, Teams, Phone) with the University of Arkansas research team. The research team member will explain the study procedures to the participants and will give them the opportunity to ask questions. During the call, they will review the electronic consent form and will sign the form after all of their questions have been answered. They will receive a paper copy of the consent documents to review one more time when they arrive at the first research session at their site.

Participants will complete two lab sessions on consecutive days (scheduled as close to 24-hours apart as possible) at a collaborating research site. At each site, a member of the local team will coordinate the sessions, including providing instructions before participants complete various study tasks. During each session, participants will complete standardized measures of decision-making that will allow us to comprehensively document how adverse provider conditions (acute inflammation, burnout, stress, concern about own health) affect objectivity in decision-making across multiple domains. These standardized measures include reaction time tasks and questionnaires. Participants will also complete questionnaires that assess demographic information, personality information, and questions about their experiences with adverse provider conditions (burnout, stress, other workplace demands, mood, concerns about own health). During each session, participants will provide blood samples (~3mL) that will be assayed for pro-inflammatory cytokines interleukin-6 and interleukin-1beta. Participants will be randomly assigned to either the experimental or control condition using stratified permuted block randomization. Those in the experimental condition will receive the influenza vaccine at the end of Session 1 and those in the control condition will receive a saline placebo injection instead. We will use a double-blind design so that neither the participant nor the research assistant administering the decision-making tasks will know the condition.

At the end of the second session, participants will be debriefed and informed about the condition they were assigned to (up until this point, the research coordinator and participant will be blind to participant condition). Those in the control condition will receive the vaccine before they leave.

연구 유형

중재적

등록 (추정된)

210

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Anastasia Makhanova, PhD
  • 전화번호: 479-575-8798
  • 이메일: ammakhan@uark.edu

연구 장소

    • Arkansas
      • Fayetteville, Arkansas, 미국, 72703
        • 모병
        • University of Arkansas for Medical Sciences
        • 연락하다:
        • 수석 연구원:
          • Roy Kamoga, MD
    • New Mexico
      • Albuquerque, New Mexico, 미국, 87106
        • 모병
        • University of New Mexico Health Sciences Center
        • 연락하다:
        • 수석 연구원:
          • Joe Alcock, MD
    • Virginia
      • Roanoke, Virginia, 미국, 24016
        • 모병
        • Carilion Medical Center
        • 수석 연구원:
          • Michael Wilson, MD
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Healthcare providers currently employed in emergency medicine or internal medicine
  • Must be one of the following: Resident, fellow, attending, or advanced practice provider (NP, PA)
  • Individual is able to travel to the research site for sessions
  • Has not had an acute viral or bacterial infection within the previous 14 days
  • Has not taken an antiviral medication such as Tamiflu in the previous 48 hours
  • Has not taken corticosteroids or immunosuppressants in the previous 30 days

Exclusion Criteria:

  • Does not want to receive a flu vaccine as part of the study
  • Has received a flu vaccine this season already (after August of current year)
  • Has had a prior allergic reaction or bad side effect, including Guillain-Barre, due to a flu vaccine or another vaccine
  • Is allergic to eggs or have had an adverse reaction to egg-derived vaccine
  • Is pregnant or suspects a possible pregnancy
  • Has congenital or acquired immunodeficiency such as common variable immunodeficiency (CVID) or HIV/AIDS
  • Has an active hematologic malignancy (like leukemia, lymphoma, myeloma)
  • Has Type 1 diabetes
  • Has Graft vs. Host Disease
  • Uses aspirin, ibuprofen (i.e., NSAIDs), acetaminophen, or naproxen daily
  • Uses corticosteroids or immunosuppressants daily
  • Is currently receiving systemic chemotherapy and/or immunotherapy
  • Has had changes in daily prescription medication in the last 3 months (starting, stopping, changing dose)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 건강 서비스 연구
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Influenza Vaccine Injection

Receives the influenza vaccine at the end of Session 1

A single administration of a seasonal trivalent cell-based influenza vaccine delivered by injection into the arm at the end of the first study session.

위약 비교기: Placebo Injection

Receives a saline placebo injection at the end of Session 1

Control group will receive a saline placebo injection at the end of Session 1

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Testing Automatic Judgments: "Implicit Association Test"
기간: 2 days

This task calculates a "d" score across trials to quantify the strength of implicit associations. Higher d scores indicate more negative automatic attitudes.

2 days
Testing Deliberate Judgments: "Feeling Thermometers"
기간: 2 days

Explicit attitudes are assessed via 100-point Feeling Thermometers that ask for feeling toward different patient groups. Lower values indicate more negative attitudes.

2 days

2차 결과 측정

결과 측정
측정값 설명
기간
Questionnaire Assessing Social Avoidance: "Patient Sorting Task"
기간: 1 day

A behavioral decision-making task order patients within an array of three. The three patients are arranged in an order in which the participant would choose to see them. The outcome is the number of trials when a patient from a target group is seen later than a patient from a control group. Higher values indicate greater potential for treatment inconsistencies.

1 day
Questionnaire Assessing Perception of Others' Pain: "Threshold for Detecting Pain on Faces"
기간: 2 days

Participants will see 11 images of targets of different racial groups that have each been morphed to go from no pain to high pain, responding to a yes/no question about whether the target is in pain in each image. The threshold at which participants begin perceiving pain will be calculated for each target and averaged within racial groups. Differences between groups indicate potential for greater treatment inconsistencies.

2 days
Questionnaire Assessing Cognitive Depletion: "Stroop Task"
기간: 2 days

To measure the delay in reaction time between neutral and incongruent stimuli. The task calculates an interference score across many trials to show the difference in response latency between incongruent and congruent trials. Greater interference is a measure of cognitive depletion.

2 days
Questionnaire Assessing Motivation: "Motivation to Respond without Prejudice Scale"
기간: 2 days

It is administered on a scale of 1 to 9, and the questions are about both internal and external motivation. Higher scores represent more motivation.

2 days

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 1일

기본 완료 (추정된)

2027년 10월 1일

연구 완료 (추정된)

2027년 12월 1일

연구 등록 날짜

최초 제출

2026년 9월 14일

QC 기준을 충족하는 최초 제출

2026년 9월 21일

처음 게시됨 (실제)

2026년 9월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 25일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • R01MD019051 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다